CGI Complete

CGI’s Complete™ Program

Cancer Genetics’ Complete™ offering is a unique suite of common and proprietary tests that assists clinicians in determining the best treatment options to improve patient outcomes. Each program integrates the latest diagnostic and prognostic biomarkers across multiple methodologies. CGI offers Complete™ testing for a number of hematological neoplasms and solid tumor cancers, including CLL/SLL, DLBCL, MCL, MPN, colorectal, lung, and breast cancers.

CGI’s Complete Testing for Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is a bone marrow cancer that progresses rapidly creating a therapeutically challenging disease to accurately diagnose and prognosticate. Bone marrow analysis with cytogenetics is used to predict remission rates, relapse risks, and overall survival outcomes. Molecular markers such as mutations and small insertions/deletions exhibit clinical relevance by helping to refine prognostic groups. Common molecular markers include CEBPA, FLT3-ITD, cKIT, and NPM1. Interpretation of the clinical relevance of mutations in AML must be considered in the context of cytogenetic-risk categories but also with respect to other mutations.

By offering the most comprehensive testing panel available, CGI’s AML Complete™ Program can help in determining the best personalized course of action for the patient.

AML Complete


AML Complete Work Flow
This workup is intended as a guide for the comprehensive suite of diagnostic tests included in AML Complete™ to diagnose and monitor AML. Physicians can order tests individually or allow CGI pathologists and directors to determine a panel evaluation as determined necessary. Tests offered through CGI’s Complete™ Programs are also available via Digital Pathology.
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
TAT2-4 days
MethodologyIHC
Specimen RequirementsFFPE tissue block at room temp. or 0.5 cm3 fresh tissue in RPMI on dry ice
CPT Codes88342
TAT1-2 days
The lymphoid panel determines expression levels of cell surface antigens by flow cytometry that provide diagnostic information for the diagnosis and for monitoring therapy. This panel includes CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD71, CD117, HLA-DR, sKappa, sLambda.
MethodologyFlow cytometry
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (2 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis of leukemia and lymphoma and for post-treatment follow-up.
CPT Codes88184; 88185 (x17); 88189
TAT1-2 days
Designed for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN), Focus::Myeloid™ is a unique NGS panel with 54 biomarkers that provides actionable information for improved diagnosis, prognosis, and risk stratification.
MethodologyNext Generation Sequencing
Analytical Sensitivity5%
Specimen RequirementsOne Lavender (EDTA) tube of peripheral blood or bone marrow aspirate. Minimum: 2-3 mL. Shipped at room temperature.
Clinical IndicationsFor the diagnosis, prognosis, and risk stratification of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloproliferative Neoplasms (MPN)
CPT Codes81455
TAT10-14 days
MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81403
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity10%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis and clinical management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
CPT Codes81263
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity20%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81404
TAT7-10 days
MethodologyPCR, sequencing
Analytical Sensitivity5%
Specimen Requirements1 Lavender/EDTA tube (2-3 ml) peripheral blood or bone marrow at room temp. or 2-8°C.
Clinical IndicationsFor the prognosis of patients with acute myeloid leukemia (AML).
CPT Codes81310
TAT7-10 days
MethodologyG-banding
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood, bone marrow or disaggregated tissue at room temp.
CPT Codes88237; 88262; 88280; 88291
TAT5-7 days
MethodologyFluorescence in situ hybridization (FISH)
Specimen Requirements1 Green/NaHeparin or 1 Lavender/EDTA tube (3-5 ml) peripheral blood or bone marrow at room temp.
Clinical IndicationsFor the diagnosis, subtyping and prognostic stratification of acute myeloid leukemia (AML) patients.
CPT Codes88271(8); 88275(4); 88291
TAT3-5 days